Research programme: tumour suppressing gene therapies - Introgen

Drug Profile

Research programme: tumour suppressing gene therapies - Introgen

Alternative Names: INGN 402; INGN 403; Nanoparticle formulation mda-7; Nanoparticle formulation p53

Latest Information Update: 18 Feb 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Introgen Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference; Interleukin 24 stimulants; P53 gene stimulants; Tumour suppressor gene transcription stimulants; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 04 Feb 2008 Preclinical development is ongoing for INGN 402 and INGN 403 in Solid tumours
  • 17 Jan 2007 Preclinical data added to the drug interactions section
  • 14 Dec 2006 Preclinical development still ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top